Posters & Presentations
Crohn’s & Colitis Congress 2024
Encouraging Efficacy of VT1021 in Preclinical Models of DSS-Induced Colitis
>> View Poster
ASCO 2023
Immune Profiling in Recurrent Glioblastoma Subjects Treated with VT1021 in a Phase I/II Expansion Study
>> View Poster
SNO 2021
Clinical efficacy and biomarker assessment of VT1021, a CD36/CD47 dual-targeting agent, in recurrent glioblastoma
>> View Poster
SITC 2021
Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers
>> View Poster
>> Presentation Audio
Development of Thrombospondin-1 as a clinical pharmacodynamic biomarker for VT1021, a first-in-class therapeutic agent that reprograms the tumor microenvironment.
ESMO 2019
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumor
>> View Poster
ASCO 2019
A phase 1 open label study evaluating VT1021 in patients with advanced solid tumors
>> View Poster